Sanofi
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Sanofi sits in the top decile of US sponsors by registered trial count (#47 of 15,742 sponsors by registered trial count).
Sanofi: 713 sponsored US clinical trials, 69 recruiting.
Sanofi sponsors 713 registered US clinical trials on ClinicalTrials.gov, 69 of them currently recruiting, and 490 completed. 364 of these trials are in Phase 3-4 (later-stage) and 316 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dermatitis, Atopic, with 9 trials.
Top-decile sponsor footprint
Sanofi ranks in the top decile of sponsors by registered trial count (#47 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
490 of 597 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
713 total, page 11 of 15
A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)
NCT00514917
Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus
NCT00495885
Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors
NCT00485719
Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
NCT00489736
Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or Lymphoma
NCT00486135
Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis
NCT00489489
Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis
NCT00475865
Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study
NCT00464243
Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus
NCT00464061
A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older
NCT00457249
Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)
NCT00464633
Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer
NCT00446030
Study of Triamcinolone Acetonide on the Growth Velocity of Children, Ages 3 to 9, With Perennial Allergic Rhinitis (PAR)
NCT00449072
A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes
NCT00449605
Efficacy and Safety of HMR1766 in Patients With Fontaine Stage II Peripheral Arterial Disease
NCT00443287
Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia
NCT00439634
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
NCT00417079
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
NCT00422682
A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression
NCT00429260
Multicenter Evaluation of Docetaxel, Gemcitabine, and Bevacizumab Combination Followed by Bevacizumab Alone in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT00378573
An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder
NCT00415142
Evaluation of the Potential Effects of SSR149415 on the Hypothalamic-pituitary-adrenal Axis in Outpatients With Major Depressive Disorder
NCT01606384
Open Label, Phase I ZD6474 Head and Neck Cancer Study
NCT00450138
Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen
NCT00417209
Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation
NCT00396877
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
NCT00396591
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children
NCT00391391
Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00803049
Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
NCT00387907
A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
NCT00390650
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
NCT00355121
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS)
NCT00385307
Docetaxel and Oxaliplatin in Gastric Cancer
NCT00382720
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder
NCT00390533
Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
NCT00380302
Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)
NCT00387946
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects
NCT00388583
Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
NCT00327743
Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer
NCT00364611
Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
NCT00365365
An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder
NCT00374166
Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
NCT00366795
An Eight-Week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Major Depressive Disorder
NCT00358631
Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)
NCT00358878
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
NCT00327444
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
NCT00356122
Insulin Glulisine in Type 2 Diabetic Patients
NCT00360698
Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology
NCT00629720
Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver
NCT00359437
Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach
NCT00345618
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 147 |
| Phase 2 | 169 |
| Phase 3 | 295 |
| Phase 4 | 69 |
What is open in the Sanofi pipeline
69 recruiting of 713 indexed (10% open); 490 completed (69%).
Phase mix: 364 late (III/IV) vs 316 early (I/II) (balanced across stages).
Top condition: Dermatitis, Atopic (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Sanofi: open-pipeline peers nationwide
Peers matched on 713 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Sanofi sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 713 trials (± recruiting share)
- Icahn School of Medicine at Mount Sinai · 708 trials · 23% recruiting
- University of Miami · 721 trials · 20% recruiting
- Weill Medical College of Cornell University · 701 trials · 18% recruiting
- The University of Texas Health Science Center, Houston · 732 trials · 20% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Children's Hospitals and Clinics of Minnesota · 10% recruiting · 31 trials
- Cytokinetics · 10% recruiting · 31 trials
- Children's Oncology Group · 10% recruiting · 342 trials
- University of North Carolina, Chapel Hill · 10% recruiting · 1,109 trials
Related
What to do with this Sanofi page
713 registered trials is a research-attention snapshot, not an endorsement of Sanofi or any single study.
- 69 of Sanofi's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dermatitis, Atopic is the condition Sanofi studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dermatitis, Atopic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Sanofi pipeline card: 713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.